Aton Pharma launches generic timolol maleate

Lawrenceville, NJ

-Aton Pharma Inc. has launched an authorized generic version of its timolol maleate ophthalmic gel-forming solution (Timoptic-XE). The non-selective beta-adrenergic receptor blocking agent is indicated in the treatment of elevated IOP in patients with ocular hypertension or open-angle glaucoma. The company also will continue to make available timolol maleate under the brand name.

“Authorized generics are a very effective sales strategy for Aton Pharma’s product portfolio,” said Michael G. Wells, the company’s chief executive officer. “We are extremely pleased with the successful launch of the authorized generic for [timolol maleate ophthalmic gel-forming solution], and we are now highly confident in our ability to execute this type of program for other Aton products when the opportunity arises.”

In related news, Aton announced that in an independent Web-based survey of 150 U.S. ophthalmologists conducted by Frost & Sullivan in November, the company’s timolol maleate ophthalmic solution (Timoptic) was rated the leading brand name of beta blockers for glaucoma. The formulation received Frost & Sullivan’s 2010 Best Practices Award as the “best brand name of beta blockers for glaucoma” based on its brand perception index score, reflecting strong brand reputation, recognition, and customer loyalty.

In the survey, 50% of respondents ranked the formulation as the top brand name of beta blockers-overwhelmingly above the nearest competitor, according to the company. Overall, 54% of the ophthalmologists surveyed said they use the drug as their primary beta-blocker product for the treatment of glaucoma. Among those who reported using it, nearly all reported the drug as one of the top three beta blockers for glaucoma.